Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
952
Employees952
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
952
Employees952

NVAX Key Statistics

Market cap
1.43B
Market cap1.43B
Price-Earnings ratio
5.34
Price-Earnings ratio5.34
Dividend yield
Dividend yield
Average volume
8.02M
Average volume8.02M
High today
$9.35
High today$9.35
Low today
$8.74
Low today$8.74
Open price
$9.22
Open price$9.22
Volume
2.03M
Volume2.03M
52 Week high
$10.64
52 Week high$10.64
52 Week low
$5.01
52 Week low$5.01

Stock Snapshot

Novavax(NVAX) stock is priced at $8.78, giving the company a market capitalization of 1.43B. It carries a P/E multiple of 5.34.

On 2026-01-30, Novavax(NVAX) stock traded between a low of $8.74 and a high of $9.35. Shares are currently priced at $8.78, which is +0.4% above the low and -6.1% below the high.

Novavax(NVAX) shares are trading with a volume of 2.03M, against a daily average of 8.02M.

In the last year, Novavax(NVAX) shares hit a 52-week high of $10.64 and a 52-week low of $5.01.

In the last year, Novavax(NVAX) shares hit a 52-week high of $10.64 and a 52-week low of $5.01.

NVAX News

Nasdaq 1d
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?

Key Points Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain. There is also ple...

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Simply Wall St 5d
Novavax Is Up 14.5% After Licensing Matrix-M Adjuvant Platform To Pfizer – Has The Bull Case Changed?

In January 2026, Novavax announced a non-exclusive worldwide License and Option Agreement granting Pfizer access to its Matrix-M adjuvant technology for vaccine...

Novavax Is Up 14.5% After Licensing Matrix-M Adjuvant Platform To Pfizer – Has The Bull Case Changed?

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
11.1%
Sell
33.3%

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.